Pseudoprogression after glioma therapy: a comprehensive review. - Wikidata - wikimedia - TriplyDB

Pseudoprogression after glioma therapy: a comprehensive review.

Pseudoprogression after glioma therapy: a comprehensive review.

http://www.wikidata.org/entity/Q38094809

about

Circulating glioma biomarkers Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma Post-treatment imaging changes in primary brain tumors.Current status and future role of brain PET/MRI in clinical and research settings.The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.Recurrent malignant gliomas.Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients.From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.Advances in treating glioblastoma.Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Challenges in the delivery of therapies to melanoma brain metastases.Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.Pseudoprogression in pediatric low-grade glioma after irradiation.PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors.Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.Usefulness of positron emission tomographic studies for gliomas.Pseudoprogression as an adverse event of glioblastoma therapy.Serial diffusion tensor imaging for early detection of radiation-induced injuries to normal-appearing white matter in high-grade glioma patients.EMP-induced BBB-disruption enhances drug delivery to glioma and increases treatment efficacy in rats.Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.Pseudoprogression after glioma therapy: an update.Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.Pseudoprogression after proton radiotherapy for pediatric low grade glioma.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model.

P2860

Q26830329-EBA7DA71-29C1-46E0-8EEB-857582DC7E69 Q30413487-15B86459-DDB5-496A-8B24-BFB591BDBB35 Q30835236-CD248F60-C83A-43C2-811A-CB130CC7973D Q30883711-72340965-AEEF-4FD2-A5B2-DC43A9CB3CD7 Q31156299-D236E548-A9FC-4BDE-BD91-2CC5ED686410 Q34438507-51B88BCD-956F-4BF4-AC11-3C280615CF9E Q34886836-90CD208D-F1AA-4F7D-B095-83E4081FDD8E Q35028818-81D50336-E4B3-4316-B12F-4BC10CF7928D Q35679377-8C9BF5EF-A686-4044-B3EA-5E9A040C6E59 Q37321862-DDC97202-99FB-460F-B0A9-87148C2A563C Q38225873-11C242BF-3C1A-4B66-B8C9-F5785E5BC737 Q38266418-06E25520-6945-4F49-B0CC-26117FBF513E Q39030177-711ED148-1132-42EF-A9D7-06BE1AF5901A Q39312420-6F102787-9408-4D2E-B917-CE52F98F38F9 Q39331752-1DAF379F-6DCF-44E1-AE25-518DDA26BD8A Q39598112-C8603D5B-7B6B-4E23-BBF5-E77B65025B2D Q39765594-5B0AC41F-5C50-497A-A1C9-8E542F59D2B7 Q40104521-267DEC53-53F1-4BE4-A530-E0420E9C0EE7 Q41180726-F7E94A1A-D248-45AD-ABBE-BD7A0F47B6DF Q41594601-F67F0A71-75CA-45F9-94DD-06D6A62D1FD5 Q41845711-6E068E59-D88B-4107-8B29-48EA5048EF44 Q41965733-8ABD7244-3116-4B5C-869A-DEC9D35C4852 Q47164037-26D1810F-CA92-46EE-8A39-01A0DE72AEAD Q47611080-68FCE3DF-D8C7-465F-91FE-005DBDD2491C Q47653500-250CB593-937D-4079-9549-EF2BFE9C2012 Q47825877-EA4AF5F3-E2EA-4E68-96FD-E4D49931C674 Q48130815-A0C7A3E9-DF98-4349-BD52-A305AEB03221 Q48906044-F5E17993-6EED-4648-A2C9-EDC0D98C4CC4 Q52149301-5AAEA826-219E-4D9A-B884-F8BDC720D833 Q52562075-C101B827-24E3-45FC-9A85-95B77EFC49AE Q52731750-25498944-ED1E-47E0-A688-0FFBAAC7E527

P2860

Pseudoprogression after glioma therapy: a comprehensive review.

http://www.wikidata.org/entity/Q38094809

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pseudoprogression after glioma therapy: a comprehensive review.

@en

type

label

Pseudoprogression after glioma therapy: a comprehensive review.

@en

prefLabel

Pseudoprogression after glioma therapy: a comprehensive review.

@en

P1433

Q38094809-550AF49B-3DC2-46AF-A2AF-38D5AB6F7614

P1476

Q38094809-A926714C-EE06-40C8-9BAE-EFF8E1ECCF71

P2093

Q38094809-051419CC-EC1C-4F38-A178-46FF44444611

Q38094809-0617AEE6-1D47-4804-A716-713C26E81069

Q38094809-6E6BEE2D-1EB2-4AE0-88EE-4ACE8A249E1F

P2860

Q38094809-002173D0-6A83-4BCE-BF8D-B0634A4A83CD

Q38094809-00562A1D-B45D-4073-9C7E-595505BE9585

Q38094809-012F53B5-E55B-4D5E-BD6F-1AE63E561686

Q38094809-06E0444A-CA0A-4265-B193-D3ECD777FFEA

Q38094809-095E6CAE-AE17-4C3B-9B4E-65594F7D7CCD

Q38094809-0F5C7C87-2219-4E11-AF43-5D623AEC5F65

Q38094809-134712F1-A37B-4EE2-990D-7E65E423A8DF

Q38094809-14619A53-C8F0-4D8C-9A10-8D9F423F904C

Q38094809-1F18F48B-896B-4CE8-89F0-3DC1D9BD95C1

Q38094809-1F3B23CC-5560-45CC-97FA-4D44C27FD0E9

P304

Q38094809-983233C9-7B53-4E3A-9221-666B23D9B654

P31

Q38094809-A2010069-B6B1-4EF9-B886-F763EC4A577D

P356

Q38094809-34100913-CC99-4FE4-B703-413A9A60CCD9

P433

Q38094809-BC63F85C-99CF-45FF-8D70-FD780C16B7F7

P478

Q38094809-4CA8F0AC-CE89-4A3A-8444-BD48096FD9E7

P577

Q38094809-A87F965D-75CB-41EC-9213-B4F720BD2338

P5875

Q38094809-672F9E6C-DEA8-458E-B2FD-DBE45A9B927B

P698

Q38094809-19B407B9-A6D3-4E95-837A-E6122A5DEB1E

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Pseudoprogression after glioma therapy: a comprehensive review.

@en

P2093

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

Minesh P Mehta

http://www.w3.org/2001/XMLSchema#string

Tim J Kruser

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess?

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Clinical applications of PET in brain tumors.

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

P304

389-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.13.7

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236096264

http://www.w3.org/2001/XMLSchema#string

P698

23545054

http://www.w3.org/2001/XMLSchema#string